Condition: Metastatic Breast Cancer · Sponsor: University of Louisville
This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer
This description comes directly from the study's public registry record.
Elizabeth Riley, MD · 502 562-4370 · beth.riley@louisville.edu
Kathleen Coons · 502 852-9127 · kjcoon01@louisville.edu
Always discuss trial participation with your own doctor first.
| James Graham Brown Cancer Center | Louisville, Kentucky, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04990921